ArticleJournal of thoracic disease2025
A retrospective study on the prognosis of patients with small cell lung cancer with or without interstitial pneumonia treated with postoperative chemotherapy.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is no data of postoperative chemotherapy for patients with small cell lung cancer (SCLC) and interstitial pneumonia (IP). This study aimed to compare the prognosis of patients with SCLC with or without IP treated with postoperative chemotherapy. Methods: We conducted a retrospective study to compare the prognoses of patients with SCLC with or without IP treated with postoperative chemotherapy. Consecutive patients who underwent postoperative chemotherapy during 2011-2021 were included. IP and acute exacerbation of IP were diagnosed through discussion with respirologists, pathologists, and radiologists. The primary endpoint was the 3-year overall survival (OS) rate in patients with and without IP. Results: We included 34 patients with SCLC treated with postoperative chemotherapy. The median age was 72.5 years, and the median preoperative percentage of lung capacity to the predicted value was 92.4%. Ten patients were diagnosed with IP, including six patients with usual IP (UIP). Thirty of the 34 patients (88%) had clinical stage I; however, 7 patients (21%) experienced upstaging pathologically. The 3-year OS rate of all patients was 67%. The 3-year OS rates were 68% with IP, and 69% without IP. The 3-year OS rate was 50% in patients with UIP. The 3-year disease-free survival (DFS) rate was 54% in all patients, 57% without IP, and 36% with IP. The 3-year DFS rate was 17%. The 3-year DFS rate was 17% in the UIP subgroup. The frequency of adverse events equal to or higher than grade 3 was 65% in all patients, 60% with IP, and 67% without IP. Acute exacerbation of IP was not observed in patients with IP. Conclusions: The 3-year OS rate of patients with IP was comparable to that of without IP. Postoperative chemotherapy may be beneficial and tolerable by patients with SCLC, with or without IP. Further studies with larger cohorts are necessary to clarify the efficacy and safety of postoperative chemotherapy in patients with IP. This study was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN ID 000051612).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.